International multicentre, open-label, phase IV clinical trial to evaluate the efficacy, safety and effect on quality of life of bilastine in children with allergic rhinoconjunctivitis
Allergic rhinoconjunctivitis causes frustrating symptoms like sneezing, a runny or blocked nose, and itchy, red, watery eyes. It can make school, sleep, and play difficult for children. This study tests an allergy medicine called bilastine (Bilaxten Flas 10 mg) to see how well it works and how safe it is for young people. The medicine comes as a melt-in-the-mouth tablet, which can be easier for children to take. During the trial, children take the medicine daily for 14 days. Parents or children use an electronic diary on a phone or tablet to track symptoms before and during treatment. The goal is to see if the treatment reduces allergy troubles and improves quality of life. Taking part is voluntary, and the study team will closely monitor each child's health.
At a glance
What is this study about?
Allergic rhinoconjunctivitis is a very common condition that happens when the body reacts to things like pollen, house dust mites, or animal fur. It leads to symptoms similar to hay fever, including a stuffy or runny nose, sneezing fits, and red, itchy, watery eyes. For many children, these symptoms can interrupt sleep, make it hard to focus at school, and get in the way of sports and outdoor play.
This clinical study focuses on an allergy medicine called bilastine. It is an antihistamine, which works by blocking histamine—a natural chemical the body releases during an allergic reaction. In this study, the medicine is given as a 10 mg 'orodispersible' tablet, meaning it quickly dissolves on the tongue without needing water. Researchers want to confirm how well this easy-to-take tablet relieves symptoms and whether it helps children feel better in their day-to-day lives.
Because bilastine is already an approved medicine, this is a 'Phase IV' trial. This means doctors are gathering extra real-world information about its safety and effectiveness specifically in children. By learning more about how young people respond to this treatment, doctors hope to offer better, simpler allergy care in the future.
Key takeaways
- Tests an allergy medicine (bilastine 10 mg) that melts on the tongue.
- Aimed at children with itchy eyes, sneezing, and runny or blocked noses.
- Involves taking the medicine once daily for 14 days.
- Uses an electronic diary to track allergy symptoms at home.
- Participation is entirely voluntary and won't affect regular NHS care.
Who may be eligible?
This study is designed for children and young people who have allergic rhinoconjunctivitis. Both boys and girls can take part. To be suitable, a child should be experiencing active allergy symptoms, such as an itchy, blocked, or runny nose and watery or irritated eyes.
Because the study focuses on standard allergy treatment in children, participants must be able to take the dissolving tablet as directed. A parent or guardian will need to give permission (consent) for their child to join, and older children may also be asked to give their own agreement (assent).
Children may not be able to take part if they have certain other health conditions, known severe allergies to the study ingredients, or if they are taking other medicines that could interfere with the study results. The study doctor will check all of these details before anyone joins.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- My child has symptoms of allergic rhinoconjunctivitis (eye and nose allergies).
- My child is able to take a daily melt-in-the-mouth tablet.
- A parent or guardian can help record symptoms in an electronic diary every day.
- We can attend clinic visits at the start and end of the 14-day study.
- My child is not taking other allergy medicines that clash with the study drug.
What does participation involve?
Taking part in the study lasts around two weeks. It begins with an initial clinic visit where the study team checks the child's health, confirms their allergy symptoms, and explains how to take the medicine.
Children will be asked to take one bilastine 10 mg tablet each day for 14 days. Because it is a melt-in-the-mouth tablet, it dissolves on the tongue without needing a drink of water. During these two weeks, parents or children will use an electronic diary (an app on a smartphone or tablet) to score daily allergy symptoms, noting how their nose and eyes are feeling.
There will be follow-up contact and a final clinic visit around day 14. At this visit, the team will review the diary entries, check for any side effects, and see how much the child's symptoms and daily quality of life have improved.
Potential risks and benefits
Locations (3)
- —UnverifiedPoland
- —UnverifiedSpain
- —UnverifiedItaly
Common questions
What is an orodispersible tablet?
It is a tablet that melts quickly on the tongue, so your child does not need to swallow it whole with water.
Will this medicine make my child drowsy?
Bilastine is a newer type of antihistamine designed not to cause sleepiness, but the doctors will monitor each child to see how they feel.
How long does the study last?
The main treatment period lasts for 14 days, with visits at the start and end of this two-week period.
What is the e-diary used for?
The e-diary is a simple digital log where you or your child record daily allergy symptoms so the researchers can track changes over time.
Can we leave the study early if we change our minds?
Yes. You can withdraw your child from the trial at any point without giving a reason, and their regular medical care will not change.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.